21.19

1.53% +0.32

After Hours: 20.818 -0.372 -1.76%

Prothena Corporation plc (PRTA)

Overview News Price History Option Chain Why PRTA Down? Discussions Forecast

Prothena Corporation plc stock is currently priced at $21.19, with a 24-hour trading volume of 592.31K. It has seen a +1.53% increased in the last 24 hours and a -14.45% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $20.80 pivot point. If it approaches the $21.25 resistance level, significant changes may occur.

Previous Close:

$20.87

Open:

$21.21

24h Volume:

592.31K

Market Cap:

$1.14B

Revenue:

$91.37M

Net Income/Loss:

$-147.03M

P/E Ratio:

-14.92

EPS:

-1.42

Net Cash Flow:

$-136.72M

1W Performance:

-0.47%

1M Performance:

-14.45%

6M Performance:

-40.73%

1Y Performance:

-59.73%

1D Range:

$20.91

$22.09

52W Range:

$19.65

$79.65

Prothena Corporation plc Stock (PRTA) Company Profile

Name

Prothena Corporation plc

Sector

Healthcare (1199)

Industry

Biotechnology (687)

Phone

353 1 236 2500

Address

Adelphi Plaza, Upper George's Street, Dún Laoghaire

Employee

125

Twitter

@ProthenaCorp

Next Earnings Date

2024-05-14

Latest SEC Filings

PRTA's Discussions on Twitter

Prothena Corporation plc Stock (PRTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Apr-24-23	Initiated	SVB Securities	Outperform
Jan-27-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral
Jun-08-21	Reiterated	Oppenheimer	Outperform
May-26-21	Initiated	Citigroup	Buy
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-12-21	Upgrade	Jefferies	Hold → Buy
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy
Dec-07-20	Initiated	H.C. Wainwright	Buy
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform
Nov-19-19	Upgrade	Evercore ISI	In-line → Outperform
May-21-18	Downgrade	Barclays	Equal Weight → Underweight
Apr-23-18	Downgrade	Jefferies	Buy → Hold
Apr-05-18	Reiterated	Barclays	Overweight
Nov-20-17	Downgrade	Wedbush	Outperform → Neutral
Sep-29-17	Reiterated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-11-17	Initiated	Jefferies	Buy
Apr-12-17	Initiated	Cantor Fitzgerald	Overweight
Apr-12-17	Initiated	Piper Jaffray	Overweight
Mar-02-17	Initiated	Instinet	Buy
Dec-21-16	Initiated	SunTrust	Buy
Nov-03-16	Initiated	Deutsche Bank	Buy
Aug-04-16	Reiterated	Barclays	Overweight
May-13-16	Initiated	Barclays	Overweight
Feb-19-16	Reiterated	Wedbush	Outperform
Jan-21-16	Initiated	Credit Suisse	Outperform

View All

Prothena Corporation plc Stock (PRTA) Latest News

Prothena Corporation plc Stock (PRTA) Financials Data

Prothena Corporation plc (PRTA) Revenue 2024

PRTA reported a revenue (TTM) of $91.37 million for the quarter ending December 31, 2023, a +69.50% rise year-over-year.

Prothena Corporation plc (PRTA) Net Income 2024

PRTA net income (TTM) was -$147.03 million for the quarter ending December 31, 2023, a -25.72% decrease year-over-year.

Prothena Corporation plc (PRTA) Cash Flow 2024

PRTA recorded a free cash flow (TTM) of -$136.72 million for the quarter ending December 31, 2023, a -25.10% decrease year-over-year.

Prothena Corporation plc (PRTA) Earnings per Share 2024

PRTA earnings per share (TTM) was -$2.80 for the quarter ending December 31, 2023, a -11.55% decline year-over-year.

Prothena Corporation plc Stock (PRTA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Walker Karin L	Chief Accounting Officer	Jan 24 '24	Sale	34.00	5,000	170,000	0
Walker Karin L	Chief Accounting Officer	Dec 20 '23	Option Exercise	13.53	5,000	67,650	5,000
Walker Karin L	Chief Accounting Officer	Dec 20 '23	Sale	37.19	5,000	185,952	0
Walker Karin L	Chief Accounting Officer	Nov 30 '23	Option Exercise	13.53	5,000	67,650	5,000
Walker Karin L	Chief Accounting Officer	Nov 30 '23	Sale	34.00	5,000	170,000	0
Walker Karin L	Chief Accounting Officer	Oct 25 '23	Option Exercise	13.53	5,000	67,650	5,000
Walker Karin L	Chief Accounting Officer	Oct 25 '23	Sale	41.04	5,000	205,191	0
Smith Brandon S.	Chief Operating Officer	Oct 11 '23	Option Exercise	11.12	4,000	44,480	4,000
Smith Brandon S.	Chief Operating Officer	Oct 11 '23	Sale	46.75	4,000	186,985	0
Karp Carol D.	Chief Regulatory Officer	Oct 04 '23	Option Exercise	12.15	5,000	60,750	5,000

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.